- Home
- PLBY vs IFRX Comparison
PLBY vs IFRX Comparison
Compare PLBY & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLBY
- IFRX
- Stock Information
- Founded
- PLBY 1953
- IFRX 2007
- Country
- PLBY United States
- IFRX Germany
- Employees
- PLBY N/A
- IFRX N/A
- Industry
- PLBY Recreational Games/Products/Toys
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- PLBY Consumer Discretionary
- IFRX Health Care
- Exchange
- PLBY Nasdaq
- IFRX Nasdaq
- Market Cap
- PLBY 113.4M
- IFRX 117.8M
- IPO Year
- PLBY N/A
- IFRX 2017
- Fundamental
- Price
- PLBY $0.97
- IFRX $1.06
- Analyst Decision
- PLBY Buy
- IFRX Strong Buy
- Analyst Count
- PLBY 2
- IFRX 2
- Target Price
- PLBY $2.35
- IFRX $9.00
- AVG Volume (30 Days)
- PLBY 442.3K
- IFRX 351.2K
- Earning Date
- PLBY 05-08-2025
- IFRX 05-07-2025
- Dividend Yield
- PLBY N/A
- IFRX N/A
- EPS Growth
- PLBY N/A
- IFRX N/A
- EPS
- PLBY N/A
- IFRX N/A
- Revenue
- PLBY $116,135,000.00
- IFRX $171,642.00
- Revenue This Year
- PLBY $5.30
- IFRX $106.72
- Revenue Next Year
- PLBY $2.08
- IFRX $66.89
- P/E Ratio
- PLBY N/A
- IFRX N/A
- Revenue Growth
- PLBY N/A
- IFRX 162.79
- 52 Week Low
- PLBY $0.52
- IFRX $0.82
- 52 Week High
- PLBY $2.44
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- PLBY 36.46
- IFRX 43.43
- Support Level
- PLBY $0.90
- IFRX $0.82
- Resistance Level
- PLBY $1.03
- IFRX $1.12
- Average True Range (ATR)
- PLBY 0.09
- IFRX 0.14
- MACD
- PLBY 0.02
- IFRX 0.03
- Stochastic Oscillator
- PLBY 26.92
- IFRX 49.58
About PLBY PLBY Group Inc.
PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.